Cisplatin-based chemotherapy in recurrent or high risk ovarian granulosa-cell tumor patients.

Abstract

Nine chemotherapy-naive women with recurrent (2 patients) or high risk factors (bilateral or extraovarian spread, poorly-differentiated tumor, age > or = 40 years at diagnosis, residual disease after surgery) granulosa-cell tumors were treated with cisplatin, cyclophosphamide with or without doxorubicin (PAC, PC) or cisplatin, etoposide and bleamycin (PVP-16B). Toxicity was acceptable and the most frequently encountered adverse reactions were WHO grade 3 gastrointestinal toxicity in 77% of patients, and grade 3 myelosuppression in 22% of cases. Clinical complete response was achieved in the 2 patients with recurrent disease. Five patients underwent second look surgery which documented: complete response in 3 patients, partial response in 1 patient and progressive disease in 1 case. Median survival was 85 months (range 14-103). Cisplatin-based cytotoxic regimens may be of benefit in the treatment of recurrent or high risk granulosa-cell tumors.

• Authors: S Chiara, L Merlini, E Campora, M Bruzzone, S Giudici, R Rosso, N Ragni
• Journal: European journal of gynaecological oncology (Eur J Gynaecol Oncol) Vol. 14 Issue 4 Pg. 314-7 ( 1993) ISSN: 0392-2936 [Print] Singapore
• PMID: 8344327 (Publication Type: Journal Article)

Chemical References

• Cisplatin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Chemotherapy, Adjuvant
• Cisplatin (administration & dosage)
• Female
• Granulosa Cell Tumor (drug therapy)
• Humans
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy, surgery)
• Ovarian Neoplasms (drug therapy, surgery)
• Risk Factors
• Treatment Outcome